Welcome to our dedicated page for REPH news (Ticker: REPH), a resource for investors and traders seeking the latest updates and insights on REPH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REPH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REPH's position in the market.
Recro Pharma, Inc. is rebranding as Societal CDMO, Inc., effective March 22, 2022, to reflect its transformation after acquiring IriSys, Inc. The name change is part of a strategy to enhance service offerings and expand operations across the U.S. Societal CDMO aims to strengthen its position in small molecule therapeutic development and attract a broader customer base. The change will not affect stockholder rights, and trading will continue under the existing ticker REPH until market close on March 21, 2022. The new identity aligns with the company's mission: 'Bringing Science to Society.'
Recro Pharma (NASDAQ: REPH) reported Q4 2021 revenue of $22.3 million, a 125% increase year-over-year, contributing to a full-year revenue of $75.4 million, up 13% compared to 2020. The company tripled its customer base and achieved a 63% growth in organic new business, rising to 147% when including the IriSys acquisition. Despite these gains, Recro reported a net loss of $2.4 million in Q4 and $11.4 million for the year. The company anticipates 2022 revenue between $90 million and $95 million, with a projected net loss range of ($13.2) million to ($11.2) million.
Recro Pharma has announced significant advancements in its contract development and manufacturing (CDMO) capabilities, including new fill/finish and lyophilization services. Construction and equipment installation at their San Diego facility are complete, with operations expected to commence in Q2 2022. The company has secured commitments from multiple clients for projects utilizing these new capabilities, which will enhance revenue opportunities. The aseptic filling can process 2,000 vials/hour, while the lyophilization unit can handle 9,000 vials every 3-5 days. Recro aims to be an end-to-end service provider for customers.
Recro Pharma, Inc. (NASDAQ: REPH) announced the release of its fourth quarter and year-end financial results for 2021 on March 1, 2022, after market close. The company will hold a conference call at 4:30 p.m. ET to discuss these results and operational highlights. Recro specializes in contract development and manufacturing, focusing on small molecule therapeutics, with facilities in Gainesville, Georgia, and San Diego, California.
Recro Pharma (REPH) announced a multi-year contract valued at $1.5 million from a U.S. government department to develop and manufacture a topical dermal treatment aimed at preventing skin cancer. The scope includes formulating a drug product with a specified active ingredient and placebo, along with associated services such as analytical method development and clinical trial material manufacturing. This contract signifies Recro's expanding role in clinical research for preventative therapies and highlights its capabilities in addressing complex pharmaceutical manufacturing challenges.
Recro Pharma has appointed Eduardo Uribe as the head of quality for its San Diego operations. With over 30 years of experience in quality systems within the biotechnology sector, Uribe's addition marks a strategic move to enhance the company's leadership team as it integrates its West Coast operations. CEO David Enloe emphasized that Uribe's expertise will strengthen Recro's commitment to quality, a critical pillar of the organization. The company aims to leverage this leadership to grow its business and expand client relationships.
Recro Pharma, Inc. (REPH), a contract development and manufacturing organization, announced the hiring of new technical operations staff in a recent press release. To incentivize these hires, Recro's board approved inducement stock option grants totaling 46,110 shares, with a ten-year term and monthly vesting over four years. The options have an exercise price based on the stock's closing price on December 31, 2021. Recro specializes in small molecule therapeutic development and offers services from pre-IND development to commercial manufacturing.
Recro Pharma (REPH) has announced that CEO David Enloe will present at the H.C. Wainwright BioConnect 2022 Conference, taking place from January 10-13, 2022. The conference will be held virtually, and Enloe's presentation will be available online starting January 10. Interested parties can access the presentation via the 'Events' page on Recro's investor website, where an archived version will be available for 30 days. Recro is a leading contract development and manufacturing organization focused on small molecule therapeutic development.
Recro Pharma (NASDAQ: REPH) announced CEO David Enloe will participate in a fireside chat during the Stephens Annual Investment Conference | NASH2021. The conference runs from December 1-3, 2021, and the chat is scheduled for December 3 from 11:00-11:45am CT. Attendees can access a live audio webcast on the company's website, with an archived version available for 30 days post-event. Recro specializes in contract development and manufacturing, focusing on complex challenges in small molecule therapeutic development.
Recro Pharma (NASDAQ: REPH) announces a strategic acquisition of IriSys, enhancing its capabilities and customer pipeline. The company reported Q3 2021 revenues of $18.2 million, a 6% decrease year-over-year, attributed to timing of customer orders. Annual revenue guidance has been increased to $74-$76 million. The acquisition is expected to diversify revenue streams and improve operational efficiency. Recro's net loss for Q3 2021 was $3.5 million, compared to a loss of $2.1 million in Q3 2020. The company has also signed several new contracts, expanding its manufacturing capabilities.
FAQ
What is the market cap of REPH (REPH)?
